لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل.

المؤلفون: Hasipek M; Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH 44195, USA., Grabowski D; Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH 44195, USA., Guan Y; Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH 44195, USA., Alugubelli RR; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Tiwari AD; Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH 44195, USA., Gu X; Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH 44195, USA., DeAvila GA; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Silva AS; Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Meads MB; Department of Cancer Physiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Parker Y; Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH 44195, USA., Lindner DJ; Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH 44195, USA., Saunthararajah Y; Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH 44195, USA.; Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA., Shain KH; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Maciejewski JP; Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH 44195, USA.; Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA., Reu FJ; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA., Phillips JG; Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH 44195, USA., Jha BK; Department of Translational Hematology and Oncology Research, Cleveland Clinic Foundation, Taussig Cancer Institute, Cleveland, OH 44195, USA.; Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA.; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA.

المصدر: Cancers [Cancers (Basel)] 2021 May 28; Vol. 13 (11). Date of Electronic Publication: 2021 May 28.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE

المؤلفون: Khouri J; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH., Faiman BM; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH., Grabowski D; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Mahfouz RZ; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Department of Clinical Pathology, Menoufia University, Shebin-Elkom, Egypt., Khan SN; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Interdisciplinary Nanotechnology Centre, Aligarh Muslim University, Aligarh, India., Wei W; Taussig Cancer Institute, Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH., Valent J; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH., Dean R; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH., Samaras C; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH., Jha BK; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Lazarus H; Case Comprehensive Cancer Center, Cleveland, OH; Department of Hematology and Oncology, Seidman Cancer Center, University Hospitals, Cleveland, OH., Campagnaro EL; Case Comprehensive Cancer Center, Cleveland, OH; Department of Hematology and Oncology, Seidman Cancer Center, University Hospitals, Cleveland, OH; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI., Malek E; Case Comprehensive Cancer Center, Cleveland, OH; Department of Hematology and Oncology, Seidman Cancer Center, University Hospitals, Cleveland, OH., Reed J; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Karam MA; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Hamilton K; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Fada S; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Kalaycio M; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH., Liu H; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Sobecks R; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH., Saunthararajah Y; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH., Chew Y; Zymo Research, Irvine CA., Orloff M; Lerner Research Institute, Genomic Core Facility, Cleveland Clinic, Cleveland, OH; Department of Epidemiology, University of Arkansas for Medical Sciences, Little Rock, AR; Rockefeller Cancer Institute, University of Arkansas for Medical Sciences, Little Rock, AR., Reu FJ; Department of Hematologic Oncology and Blood Disorders, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Case Comprehensive Cancer Center, Cleveland, OH; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; Morsani College of Medicine, University of South Florida, Tampa, FL. Electronic address: frederic.reu@moffitt.org.

المصدر: Seminars in hematology [Semin Hematol] 2021 Jan; Vol. 58 (1), pp. 45-55. Date of Electronic Publication: 2020 Dec 28.

نوع المنشور: Clinical Trial, Phase I; Journal Article

بيانات الدورية: Publisher: W.B. Saunders Country of Publication: United States NLM ID: 0404514 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-8686 (Electronic) Linking ISSN: 00371963 NLM ISO Abbreviation: Semin Hematol Subsets: MEDLINE

مواضيع طبية MeSH: Multiple Myeloma*/drug therapy , Multiple Myeloma*/genetics, Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Azacitidine/adverse effects ; DNA Methylation ; Dexamethasone/adverse effects ; Humans ; Lenalidomide/pharmacology ; Lenalidomide/therapeutic use ; Treatment Outcome

المؤلفون: Durie BGM; Cedars Sinai Cancer Center, Los Angeles, CA, USA. BDurie@myeloma.org., Hoering A; SWOG Statistical Center, Seattle, WA, USA., Sexton R; SWOG Statistical Center, Seattle, WA, USA., Abidi MH; Michigan State University/Spectrum Health Cancer Center, Grand Rapids, MI, USA., Epstein J; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA., Rajkumar SV; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Dispenzieri A; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Kahanic SP; Sanford NCORP of the North Central Plains/ Siouxland Regional Cancer Center, Sioux City, IA, USA., Thakuri MC; Cancer Care Western NC, Asheville, NC, USA., Reu FJ; Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA., Reynolds CM; Michigan Cancer Research Consortium NCORP, St. Joseph Mercy Hospital, Ann Arbor, MI, USA., Orlowski RZ; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Barlogie B

المصدر: Blood cancer journal [Blood Cancer J] 2020 May 11; Vol. 10 (5), pp. 53. Date of Electronic Publication: 2020 May 11.

نوع المنشور: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Bortezomib/*therapeutic use , Dexamethasone/*therapeutic use , Lenalidomide/*therapeutic use , Multiple Myeloma/*drug therapy, Aged ; Female ; Follow-Up Studies ; Humans ; Male ; Survival Analysis ; Transplantation, Autologous ; Treatment Outcome

المؤلفون: Khouri J; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Kin A; Division of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., Thapa B; Department of Internal Medicine, Cleveland Clinic Fairview Hospital, Cleveland, OH, USA., Reu FJ; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Bumma N; Division of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., Samaras CJ; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Liu HD; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Karam MA; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Reed J; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Mathur S; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Faiman BM; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA., Devries G; Division of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., Zonder J; Division of Hematology/Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA., Valent J; Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.

المصدر: British journal of haematology [Br J Haematol] 2019 Apr; Vol. 185 (2), pp. 342-344. Date of Electronic Publication: 2018 Jun 25.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Antibodies, Monoclonal/*therapeutic use , Antineoplastic Agents/*therapeutic use , Immunoglobulin Light-chain Amyloidosis/*drug therapy, Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal/administration & dosage ; Antibodies, Monoclonal/adverse effects ; Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Drug Administration Schedule ; Female ; Humans ; Male ; Middle Aged ; Multiple Myeloma/drug therapy ; Recurrence ; Treatment Outcome

المؤلفون: Sidana S; Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, United States of America., Narkhede M; Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, United States of America., Elson P; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, United States of America., Hastings D; Department of Cancer Center Research, Cleveland Clinic, Cleveland, Ohio, United States of America., Faiman B; Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America., Valent J; Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America., Samaras C; Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America., Hamilton K; Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America., Liu HK; Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America., Smith MR; Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America., Reu FJ; Department of Hematology & Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.

المصدر: PloS one [PLoS One] 2017 Mar 09; Vol. 12 (3), pp. e0172996. Date of Electronic Publication: 2017 Mar 09 (Print Publication: 2017).

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE

مواضيع طبية MeSH: Amyloidosis/*drug therapy , Antineoplastic Agents/*therapeutic use , Bortezomib/*therapeutic use , Multiple Myeloma/*drug therapy , Peripheral Nervous System Diseases/*prevention & control, Adult ; Aged ; Aged, 80 and over ; Amyloidosis/complications ; Drug Administration Schedule ; Female ; Humans ; Injections, Intravenous ; Injections, Subcutaneous ; Male ; Middle Aged ; Multiple Myeloma/complications ; Multivariate Analysis ; Odds Ratio ; Retrospective Studies ; Treatment Outcome

المؤلفون: Kumar SK, Callander NS, Alsina M, Atanackovic D, Biermann JS, Chandler JC, Costello C, Faiman M, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff CA, Kassim A, Liedtke M, Martin T, Omel J, Raje N, Reu FJ, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Shead DA, Kumar R

المصدر: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2017 Feb; Vol. 15 (2), pp. 230-269.

نوع المنشور: Journal Article; Practice Guideline

بيانات الدورية: Publisher: Harborside Press Country of Publication: United States NLM ID: 101162515 Publication Model: Print Cited Medium: Internet ISSN: 1540-1413 (Electronic) Linking ISSN: 15401405 NLM ISO Abbreviation: J Natl Compr Canc Netw Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Medical Oncology/*standards , Multiple Myeloma/*diagnosis , Multiple Myeloma/*therapy , Stem Cell Transplantation/*methods, Antineoplastic Agents/supply & distribution ; Antineoplastic Combined Chemotherapy Protocols/standards ; Asymptomatic Diseases ; Chemotherapy, Adjuvant/methods ; Chemotherapy, Adjuvant/standards ; Humans ; Immunoglobulins/blood ; Magnetic Resonance Imaging ; Maintenance Chemotherapy/methods ; Maintenance Chemotherapy/standards ; Multiple Myeloma/blood ; Myeloma Proteins/analysis ; Positron Emission Tomography Computed Tomography ; Radiotherapy, Adjuvant/methods ; Radiotherapy, Adjuvant/standards ; Serologic Tests ; Standard of Care ; Stem Cell Transplantation/standards ; Treatment Outcome

المؤلفون: Vatolin S; Department of Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, Ohio., Phillips JG; Department of Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, Ohio., Jha BK; Department of Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, Ohio., Govindgari S; Cornell University, Ithaca, New York., Hu J; Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio., Grabowski D; Department of Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, Ohio., Parker Y; Department of Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, Ohio., Lindner DJ; Department of Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, Ohio. Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio., Zhong F; Division of Hematology & Oncology, University Hospitals of Cleveland, Cleveland, Ohio., Distelhorst CW; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio. Division of Hematology & Oncology, University Hospitals of Cleveland, Cleveland, Ohio., Smith MR; Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio. Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, Ohio., Cotta C; Department of Clinical Pathology, Cleveland Clinic, Cleveland, Ohio., Xu Y; Department of Chemistry, Cleveland State University, Cleveland, Ohio., Chilakala S; Department of Chemistry, Cleveland State University, Cleveland, Ohio., Kuang RR; University of Chicago, Chicago, Illinois., Tall S; Emory University, Atlanta, Georgia., Reu FJ; Department of Translational Hematology & Oncology Research, Cleveland Clinic, Cleveland, Ohio. Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio. Department of Hematology & Medical Oncology, Cleveland Clinic, Cleveland, Ohio. reuf@ccf.org.

المصدر: Cancer research [Cancer Res] 2016 Jun 01; Vol. 76 (11), pp. 3340-50. Date of Electronic Publication: 2016 Apr 06.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*pharmacology , Apoptosis/*drug effects , Endoplasmic Reticulum Stress/*drug effects , Enzyme Inhibitors/*pharmacology , Multiple Myeloma/*pathology , Protein Disulfide-Isomerases/*antagonists & inhibitors , Thiazolidines/*pharmacology , Thiones/*pharmacology, Animals ; Binding Sites ; Blotting, Western ; Cell Proliferation/drug effects ; Endoplasmic Reticulum/drug effects ; Endoplasmic Reticulum/enzymology ; Humans ; Mice ; Mice, Inbred C57BL ; Multiple Myeloma/drug therapy ; Multiple Myeloma/enzymology ; Oxidation-Reduction ; Protein Conformation ; Protein Disulfide-Isomerases/metabolism ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays